Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 August 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Low infliximab trough levels may worsen symptoms in luminal Crohn's disease

A prospective cohort study reported in this month's Alimentary Pharmacology & Therapeutics determines the relationship between serum infliximab concentration, and efficacy in patients with luminal Crohn's disease.

News image

Patients with Crohn's disease may experience disease relapse on maintenance infliximab. Anti-drug antibodies likely contribute to loss of response, and serum infliximab levels likely correlate with efficacy.

Dr Feagan and colleagues from Canada prospectively evaluated the relationship between trough serum infliximab concentration and disease activity.

Adult patients with a diagnosis of Crohn's disease who had received at least 5 consecutive infliximab infusions, and who planned to receive at least two additional infusions were enrolled.

The Crohn's Disease Activity Index (CDAI), serum infliximab, C-reactive protein (CRP) and antibodies-to-infliximab (ATI) were assessed at baseline, week 4 and week 8.

Infliximab trough concentrations below 3 μg/mL may increase the likelihood of symptoms
Alimentary Pharmacology & Therapeutics

Receiver operating characteristic (ROC) analysis examined the relationship between infliximab concentrations and disease activity.

The mean CDAI score, which decreased 1.05 points between infusions, did not correlate with the mean change in trough infliximab concentration, but was associated with the mean change in CRP concentration.

The research team found that trough infliximab concentrations below 2.84.6 μg/mL best predicted a ≥ 70 point increase in the CDAI between infusions, and those below 2.72.8 μg/mL best predicted CRP >5 mg/mL at the second infusion.

The team observed that antibodies-to-infliximab at either visit decreased the proportion of patients with therapeutic infliximab trough levels compared with patients who were antibodies-to-infliximab negative.

Dr Feagan's team concludes, "This prospective study confirms the relationship between trough infliximab concentrations, inflammation and antibodies-to-infliximab."

"Infliximab trough concentrations below 3 μg/mL may increase the likelihood of symptoms and inflammation."

Aliment Pharmacol Ther 2014: 39(10): 11261135
01 May 2014

Go to top of page Email this page Email this page to a colleague

 24 August 2016 
Genetics and therapy response in IBD
 24 August 2016 
Obeticholic acid for primary biliary cholangitis
 24 August 2016 
Hep B after infant vaccination program
 23 August 2016 
Colorectal cancer genetics as biomarkers
 23 August 2016 
Prognostic test for mortality after liver transplant
 23 August 2016 
Postoperative mortality in elderly with IBD
 22 August 2016 
Celiac disease in the elderly
 22 August 2016 
Laparoscopic vs open colectomy databases
 22 August 2016 
Mucosal healing and ulcerative colitis outcomes
 19 August 2016 
Dietary questionnaire for GI clinics
 19 August 2016 
Botox treatment for chronic anal fissure
 19 August 2016 
Myeloid-derived suppressor cells in GI cancers
 18 August 2016 
Gallstone formation determinants
 18 August 2016 
Age disparities in IBD therapy
 18 August 2016 
Seasonal variation in diverticulitis
 17 August 2016 
IBD activity score for routine clinical use
 17 August 2016 
Attitudes to H. pylori in primary care
 17 August 2016 
Nonselective β-blockers and mortality in cirrhosis
 16 August 2016 
Upper GI lesions in adults with IBD
 16 August 2016 
C. difficile infection and mortality when managed by GI surgeons
 16 August 2016 
HCV eradication in cirrhosis
 15 August 2016 
Predicting favorable outcomes in IBD
 15 August 2016 
Scoring system predicted microscopic colitis
 15 August 2016 
Mortality in spontaneous bacterial peritonitis
 12 August 2016 
Recurrence of resected gastric cancer
 12 August 2016 
Screening for pancreatic cancer
 12 August 2016 
Index for diagnostic accuracy of Crohn's
 11 August 2016 
Bowel disease in primary care patients with bowel symptoms
 11 August 2016 
Diagnosis in covert hepatic encephalopathy
 11 August 2016 
Colorectal neoplasm on surveillance colonoscopies
 10 August 2016 
Maintenance therapy for children with eosinophilic esophagitis
 10 August 2016 
Moderate alcohol use and insulin action in HCV
 10 August 2016 
Consensus on the management of GERD
 09 August 2016 
Pancreatitis quality of life instrument
 09 August 2016 
Gallstone disease and NAFLD
 09 August 2016 
Steroid dependency and IBD
 08 August 2016 
Venous thromboembolism in celiac disease
 08 August 2016 
C. diff in IBD 
 08 August 2016 
Gut-directed hypnotherapy vs low FODMAP diet in IBS
 05 August 2016 
Therapy for H.pylori treatment
 05 August 2016 
Obesity and the development of NAFLD
 05 August 2016 
Obesity and CVD in celiac disease
 04 August 2016 
Novel risk factor for post-ERCP pancreatitis
 04 August 2016 
Bleeding after endoscopic resection of colorectal lesions
 04 August 2016 
Ondansetron for children with acute gastroenteritis
 03 August 2016 
Post-colonoscopy complications
 03 August 2016 
IVF in women with IBD
 03 August 2016 
Post-operative pancreatic fistulae after pancreatic surgery
 02 August 2016 
H. pylori in children
 02 August 2016 
Gastric cancer in patients with gastric intestinal metaplasia
 02 August 2016 
Behavioral changes and bariatric surgery
 01 August 2016 
Relapse after cessation of oral antiviral treatment in Hep B
 01 August 2016 
Antimicrobial resistance of H. pylori
 01 August 2016 
Colorectal cancers in IBD
 29 July 2016 
Susceptibility loci for gallstone disease
 29 July 2016 
Tool to diagnose Helicobacter-negative gastritis
 29 July 2016 
H. pylori clarithromycin resistance in the USA
 28 July 2016 
HCV eradication in cirrhotic patients
 28 July 2016 
Hep B screening and immunosuppressive therapy
 28 July 2016 
Pancreatitis after ERCP

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us